---
title: "Cue BioPharma | 8-K: FY2025 Q2 Revenue Beats Estimate at USD 2.954 M"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/252731054.md"
published_at: "2025-08-12T20:01:51.000Z"
---

# Cue BioPharma | 8-K: FY2025 Q2 Revenue Beats Estimate at USD 2.954 M

Revenue: As of FY2025 Q2, the actual value is USD 2.954 M, beating the estimate of USD 2 M.

EPS: As of FY2025 Q2, the actual value is USD -0.09, beating the estimate of USD -0.13.

### Segment Revenue

-   Collaboration revenue: $3.0 million for Q2 2025, compared to $2.7 million for Q2 2024. The increase was due to the timing of revenue earned from the collaboration and license agreement with Boehringer Ingelheim International GmbH (BI).

### Operational Metrics

-   Research and development expenses: $7.9 million for Q2 2025, compared to $9.5 million for Q2 2024. The decrease was primarily due to decreases in clinical trials costs and employee compensation.
-   General and administrative expenses: $3.7 million for Q2 2025, compared to $3.5 million for Q2 2024. The increase was primarily due to an increase in professional fees.
-   Loss from operations: - $8.6 million for Q2 2025, compared to - $10.4 million for Q2 2024.
-   Net loss: - $8.5 million for Q2 2025, compared to - $10.2 million for Q2 2024.

### Cash Flow

-   Cash and cash equivalents: $27.5 million as of June 30, 2025, compared to $22.5 million as of December 31, 2024.

### Unique Metrics

-   Raised approximately $20 million through a public offering.
-   Upfront payment of $12 million and ~$345 million in potential milestone payments from a strategic research collaboration and license agreement with Boehringer Ingelheim.

### Outlook / Guidance

-   The company plans to submit an IND for CUE-401 to address unmet needs in the treatment of autoimmune disease.
-   The company believes that CUE-101 has the potential to establish a new standard of care for HPV+ HNSCC patients.
-   The company anticipates potential receipt of future milestone-based payments.

### Related Stocks

- [CUE.US - Cue BioPharma](https://longbridge.com/en/quote/CUE.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Cue Biopharma 已确定 2026 年年度会议日期及提案提交截止日期 | Cue Biopharma 已将其 2026 年年度会议定于 2026 年 4 月 13 日，提案提交截止日期为 2026 年 2 月 28 日。该截止日期适用于股东提案、董事提名和代理征集。CUE 股票的最新分析师评级为持有，目标价格为  | [Link](https://longbridge.com/en/news/276280551.md) |
| 谷歌突然发布 Gemini 3.1 Pro：核心推理性能直接翻倍 | 谷歌发布了最新的大模型 Gemini 3.1 Pro，其推理性能较去年发布的 Gemini 3 Pro 翻倍。在 ARC-AGI-2 评测中，Gemini 3.1 Pro 得分 77.1%，显示出强大的推理能力。新模型支持多源数据综合和复杂 | [Link](https://longbridge.com/en/news/276396515.md) |
| 沃尔玛四季度财报超预期但盈利指引不及预期，CEO 称 “美国低收入家庭只能勉强维持生计” | 沃尔玛 Q4 营收超预期，新财年盈利指引（每股 2.75-2.85 美元）远低于市场预期的 2.96 美元，显示通胀压力下消费者支出不确定性犹存，拖累股价下跌 1.38%。财报印证 K 型” 分化：高收入家庭驱动增长，低收入群体 “钱包吃紧 | [Link](https://longbridge.com/en/news/276398633.md) |
| 学习英伟达刺激芯片销售，AMD 为 “AI 云” 借款做担保 | AMD 为扩大市场份额祭出金融 “狠招”！为初创公司 Crusoe 的 3 亿美元购芯贷款提供担保，承诺在其无客户时 “兜底” 租用芯片。这一复刻英伟达 “租卡云” 路径的策略虽能短期推高销量，但也令 AMD 在 AI 需求放缓时面临更大的 | [Link](https://longbridge.com/en/news/276401504.md) |
| GRAIL｜8-K：2025 财年 Q4 营收 43.6 百万美元超过预期 |  | [Link](https://longbridge.com/en/news/276379877.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.